ACTA FAC MED NAISS 2020;37(4):
349-358|
ACTA FAC MED NAISS 2020;37(4):
349-358 |
Original article
UDC: 616.34/.36-006.6-089-085.277.4
DOI:
10.5937/afmnai2004349D
Prognostic Parameters in Patients with Resected Liver
Metastases from
Colorectal Cancer after Biological and Chemotherapy
Miljana Džunić1,
Ivan Petković1,2, Ana Cvetanović1,2, Ivica Pejčić1,2,
SUMMARY
The aim of the research was to investigate prognostic factors in patients
with resected colorectal liver metastases (CLMs) after biological and
chemotherapy, which made initially unresectable disease suitable for resection.
Sixty-six patients with resected CLMs, operated after induction
bio-chemotherapy with bevacizumab + FOLFOX4, treated at the Clinic of Oncology,
Clinical Center Niš from 2010 - 2017 were included. Disease-free survival (DFS)
and overall survival (OS) were estimated using the Kaplan-Meier method and
compared using the log‐rank test according to demographic characteristics,
characteristics of the disease and the treatment. A univariate COX regression
analysis was performed.
In patients with up to 4 CLMs, DFS was significantly longer than in
patients with five or more metastases (18,384 v.s. 6,85 months; p < 0,001).
Significantly longer OS was present in patients with up to four CLMs than in
those with five or more CLMs (44,687 v.s. 29,723 months; p=0,006) and in
patients without extrahepatic disease (41,71 v.s. 23,283 months; p=0,012). In
the univariate analysis, five or more CLMs were predictors of poorer DFS (HR
3,989; 95% CI 1,055 - 15,087; p = 0,042), whereas the absence of extrahepatic
disese was a predictor of better OS (HR 0,122; 95% CI 0,017 - 0,869; p = 0,036).
Results of this research are in concordance with previous larger studies
in patients with resected CLMs.
The number of hepatic and the
presence of extrahepatic metastases are prognostic parameters in patients with
resected CLM after conversion bio-chemotherapy.
Key words: colorectal cancer, liver,
metastases, prognosis, surgery